2Charles DS, Jack JZ, et al. Modulation of p-glycoprotein activity by estramustine is limited by binding to plasma protein[ J ]. Cancer, 1995,75 : 2597.
3Sargent J M, Tayor CG. Appraisal of the MTT assay as rapid text of chemoserksitivity in acute myeloid leukemia[J]. Br J Cancer, 1989,60-206.
4Ganapathi, R., and D. Grabowski. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells: lack of correlation between cellular doxorubicin levels and expression of resistance[J ]. Biochem Pharmaclo, 1988,37 : 185-193.
5Stein WD, Cardarelli CO. Kinetic evidence suggesting that the muhidrug transporter differentially hadles influx and efflux of its substrates[ J ]. Mol Pharrmtcol, 1994,45 : 763-772.
6Bellamy WT, Dalton WS. Muhidrug resistance in the laboratory and clinic[J ]. Adv Clin Chem, 1994,31:1-61.
7Ram G, Tien K. Relationship between expression of PGlycoprotein and dfficacy of trifluoperazine in multidrugresistant cells[J ]. Molecular Pharmacology, 39:1- 8.
8Hamada H,et ah Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein [ J ]. Cancer,1990,50:3167.
